Causeway Therapeutics is a clinical-stage Bio-pharmaceutical company that spun-out of the University of Glasgow in 2017 to develop novel microRNA therapies for the treatment of common musculoskeletal and age-related diseases.
We have an impressive pipeline of therapies including programs targeting tendinopathy, osteoarthritis, cardiovascular disease, and skin ageing, each with significant unmet clinical needs.
Where we work
Causeway is spread over two sites in Glasgow (Scotland). Our office is located within the Clinical Innovation Zone at the Queen Elizabeth University Hospital, placing us close to the Clinicians who inform our science and, importantly, the patients suffering from the diseases we aim to treat.
Our lab is located a short distance across the river Clyde on the University of Glasgow campus, giving us access to the state-of-the-art where we have access to latest cutting-edge research equipment and core research facilities, including Polyomics (RNAseq, single-cell sequencing, proteomics and bio-informatics), Flow cytometry Facility (18-colour FACS), Imaging (super-resolution microscopy, live imaging microscopy, in vivo Imaging, multi-photon microscopy and high-throughput Imaging). Access to these technologies and the experts who run them means that Causeway’s R&D capabilities are on par with large pharma companies.